Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Vaso-occlusive Crisis in Sickle Cell Disease
NCT04925492Phase 1Completed
- Start
- Nov 2022
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of 64cu-llp2a in sickle cell disease (SCD) (2 arms). Primary endpoints: Change in PET tracer uptake in VOC up to 5 years, Association of PET tracer uptake with intensity of pain in VOC at 2 hours and 1 more. Started Nov 2022; status: completed.
02
Drugs
64cu-llp2a
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04925492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925492.